1
|
DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects. Front Immunol 2023; 14:1055671. [PMID: 36793737 PMCID: PMC9922899 DOI: 10.3389/fimmu.2023.1055671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2022] [Accepted: 01/19/2023] [Indexed: 01/31/2023] Open
Abstract
TLR7 is an innate immune receptor that recognizes single-stranded RNAs, and its activation leads to anti-tumor immune effects. Although it is the only approved TLR7 agonist in cancer therapy, imiquimod is allowed to be administered with topical formulation. Thus, systemic administrative TLR7 agonist is expected in terms of expanding applicable cancer types. Here, we demonstrated the identification and characterization of DSP-0509 as a novel small-molecule TLR7 agonist. DSP-0509 is designed to have unique physicochemical features that could be administered systemically with a short half-life. DSP-0509 activated bone marrow-derived dendritic cells (BMDCs) and induced inflammatory cytokines including type I interferons. In the LM8 tumor-bearing mouse model, DSP-0509 reduced tumor growth not only in subcutaneous primary lesions but also in lung metastatic lesions. DSP-0509 inhibited tumor growth in several syngeneic tumor-bearing mouse models. We found that the CD8+ T cell infiltration of tumor before treatment tended to be positively correlated with anti-tumor efficacy in several mouse tumor models. The combination of DSP-0509 with anti-PD-1 antibody significantly enhanced the tumor growth inhibition compared to each monotherapy in CT26 model mice. In addition, the effector memory T cells were expanded in both the peripheral blood and tumor, and rejection of tumor re-challenge occurred in the combination group. Moreover, synergistic anti-tumor efficacy and effector memory T cell upregulation were also observed for the combination with anti-CTLA-4 antibody. The analysis of the tumor-immune microenvironment by using the nCounter assay revealed that the combination of DSP-0509 with anti-PD-1 antibody enhanced infiltration by multiple immune cells including cytotoxic T cells. In addition, the T cell function pathway and antigen presentation pathway were activated in the combination group. We confirmed that DSP-0509 enhanced the anti-tumor immune effects of anti-PD-1 antibody by inducing type I interferons via activation of dendritic cells and even CTLs. In conclusion, we expect that DSP-0509, a new TLR7 agonist that synergistically induces anti-tumor effector memory T cells with immune checkpoint blockers (ICBs) and can be administered systemically, will be used in the treatment of multiple cancers.
Collapse
|
2
|
Phase 1/2, open-label, dose-escalation, dose-expansion study of menin inhibitor DSP-5336 in adult patients with acute leukemia with and without mixed-lineage leukemia ( MLL)-rearrangement (r) or nucleophosmin 1 ( NPM1) mutation (m). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.16_suppl.tps7066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
TPS7066 Background: DSP-5336, a menin MLL interaction inhibitor, elicited antitumor activity in MLL–r or NPM1m acute leukemia models in vitro and in vivo. An open-label, single-arm, phase 1/2 study (NCT04988555) will evaluate the safety and efficacy of DSP-5336 and determine the recommended phase 2 dose (RP2D) in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) or acute lymphocytic leukemia (ALL). Methods: Patients aged ≥18 y with R/R AML, ALL, or acute leukemia of ambiguous lineage after ≥1 line of standard therapy, ECOG PS 0–2, and adequate organ function are eligible. Patients will receive DSP-5336 twice daily for 28 d/cycle. In phase 1, there will be two parallel escalation cohorts: patients who do not receive concomitant azole antifungal medication and patients who receive antifungal azoles (ie, posaconazole, voriconazole, or fluconazole); 21–30 patients will be enrolled during phase 1 into multiple ascending dose levels. Dose escalation will use a Bayesian logistic regression model. Phase 2 will enroll two arms: R/R AML with MLL –r and R/R AML with NPM1m (10 –20 patients/arm). Patients will be treated at the RP2D to evaluate clinical activity and safety. Clinical trial information: NCT04988555. [Table: see text]
Collapse
|
3
|
798 Autophagosome-like vacuoles in vitiligo melanocytes are associated with cell viability and intracellular glutathione levels. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.874] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
885 The secretion of TNF-α by inflammatory macrophages has dual effects on subcutaneous adipose precursor cells: inhibition of differentiation and activation of proliferation. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.961] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
5
|
747 The coexistence of riboflavin and tryptophan is responsible for the production of H2O2 in the UVA-induced cytotoxicity of dermal fibroblasts. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
6
|
Comparison of serum inflammatory cytokine concentrations in familial Mediterranean fever and rheumatoid arthritis patients. Scand J Rheumatol 2017; 47:331-333. [PMID: 28868950 DOI: 10.1080/03009742.2017.1363281] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
7
|
DEVELOPMENT OF COLLABORATION INDEX BETWEEN NURSES AND CARE WORKERS IN END-OF-LIFE CARE. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.1796] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Randomised phase II trial of irinotecan plus S-1 in patients with gemcitabine-refractory pancreatic cancer. Br J Cancer 2017; 116:464-471. [PMID: 28081543 PMCID: PMC5318973 DOI: 10.1038/bjc.2016.436] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 10/31/2016] [Accepted: 12/05/2016] [Indexed: 12/18/2022] Open
Abstract
Background: We aimed to compare the efficacy and safety of irinotecan/S-1 (IRIS) therapy with S-1 monotherapy in patients with gemcitabine-refractory pancreatic cancer. Methods: Patients were treated with oral S-1 (80–120 mg for 14 days every 4 weeks) plus intravenous irinotecan (100 mg m−2 on days 1 and 15 every 4 weeks; IRIS group) or oral S-1 group (80–120 mg daily for 28 days every 6 weeks). The primary endpoint was progression-free survival (PFS). Results: Of 137 patients enrolled, 127 were eligible for efficacy. The median PFS in the IRIS group and S-1 monotherapy group were 3.5 and 1.9 months, respectively (hazard ratio (HR)=0.77; 95% confidence interval (CI), 0.53–1.11; P=0.18), while the median overall survival (OS) were 6.8 and 5.8 months, respectively (HR=0.75; 95% CI, 0.51–1.09; P=0.13). Response rate was significantly higher in the IRIS group than in the S-1 monotherapy group (18.3% vs 6.0%, P=0.03). Grade 3 or higher neutropenia and anorexia occurred more frequently in the IRIS group. Conclusions: There was a trend for better PFS and OS in the IRIS group that could be a treatment arm in the clinical trials for gemcitabine-refractory pancreatic cancer.
Collapse
|
9
|
ONO-7643/anamorelin for the treatment of patients with non-small cell lung cancer and cachexia: results from phase 2 study with Japanese patients. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.02] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
10
|
Chemical and in vitro toxicological analysis of the vapor from a novel tobacco vaporizer with tobacco capsule. Toxicol Lett 2016. [DOI: 10.1016/j.toxlet.2016.06.2091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
11
|
Abstract
Computed tomographic (CT) features in 10 patients with germ cell tumor of the mediastinum and 15 with thymoma were compared with surgically resected specimens. The CT findings of the internal structure of tumors were the most important factor for specific diagnosis. Germ cell tumors showed a round mass without distinct lobulation, frequently with calcification appearing as a globular shape, and especially in benign tumors as an arched shape along the wall. Homogeneous low density masses (near-water) with a thick wall were benign and non-homogeneous density masses (a mixture of near-water and soft tissue) were malignant. Thymoma usually showed a solid mass with lobulation and sometimes had an eggshell type of calcification in the tumor. Therefore, CT is of importance in the diagnosis of anterior mediastinal masses.
Collapse
|
12
|
Emergence of Epstein-Barr virus-associated haemophagocytic syndrome upon treatment of systemic lupus erythematosus. Lupus 2016; 15:51-3. [PMID: 16482747 DOI: 10.1191/0961203306lu2247cr] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
A 32-year-old female patient with systemic lupus erythematosus was admitted to our hospital with fever and cytopenia, and diagnosed as haemophagocytic syndrome (HPS) by bone marrow aspiration study showing haemophagocytosis. Since the serologic activity of lupus was not increased at that time and HPS was refractory to the conventional therapies, an additional aetiological factor was suspected. Real-time PCR analysis identified reactivation of Epstein-Barr virus (EBV). A combination therapy targetting EBV-associated HPS, consisting of intravenous administration of cyclosporine A as well as immunoglobulin with a high titre of anti-EBV antibody, significantly suppressed EBV viraemia and led to the remission of HPS until the time of writing.
Collapse
MESH Headings
- Adult
- Antibodies, Viral/analysis
- Biopsy, Needle
- Bone Marrow/pathology
- DNA, Viral/analysis
- Diagnosis, Differential
- Drug Therapy, Combination
- Epstein-Barr Virus Infections/etiology
- Epstein-Barr Virus Infections/pathology
- Epstein-Barr Virus Infections/virology
- Female
- Follow-Up Studies
- Glucocorticoids/adverse effects
- Herpesvirus 4, Human/genetics
- Herpesvirus 4, Human/immunology
- Humans
- Immunosuppressive Agents/adverse effects
- Immunosuppressive Agents/therapeutic use
- Lupus Erythematosus, Systemic/complications
- Lupus Erythematosus, Systemic/drug therapy
- Lymphohistiocytosis, Hemophagocytic/etiology
- Lymphohistiocytosis, Hemophagocytic/pathology
- Lymphohistiocytosis, Hemophagocytic/virology
Collapse
|
13
|
THU0157 Clinical Outcomes at Week 104 and Analysis of Associated Baseline Factors after An Initial 1 Year of Certolizumab Pegol and MTX Treatment in MTX-Naïve Patients with Early RA: Results from The Second Year of The C-Opera Study. Ann Rheum Dis 2016. [DOI: 10.1136/annrheumdis-2016-eular.1249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
14
|
In vitro investigation of molecules involved in Lactobacillus gasseri SBT2055 adhesion to host intestinal tract components. J Appl Microbiol 2016; 120:1658-67. [PMID: 26999673 DOI: 10.1111/jam.13137] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2015] [Revised: 02/11/2016] [Accepted: 03/11/2016] [Indexed: 01/06/2023]
Abstract
AIMS The adhesion ability of Lactobacillus gasseri SBT2055 was investigated in vitro by searching for its adhesion molecules. METHODS AND RESULTS Lactobacillus gasseri SBT2055 showed adherence to host components, including two commercially available mucins, Caco-2 epithelial-like cells and the extracellular matrix molecule fibronectin (Fn). Its adhesion rates to host components were generally higher than those of other Lactobacillus strains. We examined sortase-dependent proteins (SDPs) anchored by a sortase enzyme encoded by srtA1. The adhesion rates of an srtA1 disruptant were lower than those of Lact. gasseri SBT2055, and the relative adherences were as follows: two mucins, 43 and 40%; Caco-2, 66% and Fn, 28%. Seven additional gene disruptants were generated to determine the precise SDPs that contribute to adhesion to each component. CONCLUSIONS The adhesion ability of Lact. gasseri SBT2055 was superior to those of other Lactobacillus strains. Additionally, four adhesion molecules were newly identified from candidate SDPs. SIGNIFICANCE AND IMPACT OF THE STUDY Although the contribution of SDPs to adhesion has been reported using sortase gene disruptants, this is the first report to identify the precise SDPs that act as adhesion molecules. Our results will contribute to achieving better understanding of probiotic bacterial adherence.
Collapse
|
15
|
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy. Oncotarget 2016; 7:17035-46. [PMID: 26959743 PMCID: PMC4941369 DOI: 10.18632/oncotarget.7928] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Accepted: 02/05/2016] [Indexed: 11/25/2022] Open
Abstract
Strategies to augment anti-cancer immune responses have recently demonstrated therapeutic utility. To date clinical success has been achieved through targeting co-inhibitory checkpoints such as CTLA-4, PD-1, and PD-L1. However, approaches that target co-activatory pathways are also being actively being developed. Here we report that the novel TLR7-selective agonist DSR-29133 is well tolerated in mice and leads to acute immune activation. Administration of DSR-29133 leads to the induction of IFNα/γ, IP-10, TNFα, IL-1Ra and IL-12p70, and to a reduction in tumor burden in syngeneic models of renal cancer (Renca), metastatic osteosarcoma (LM8) and colorectal cancer (CT26). Moreover, we show that the efficacy of DSR-29133 was significantly improved when administered in combination with low-dose fractionated radiotherapy (RT). Effective combination therapy required weekly administration of DSR-29133 commencing on day 1 of a fractionated RT treatment cycle, whereas no enhancement of radiation response was observed when DSR-29133 was administered at the end of the fractionated RT cycle. Combined therapy resulted in curative responses in a high proportion of mice bearing established CT26 tumors which was dependent on the activity of CD8+ T-cells but independent of CD4+ T-cells and NK/NKT cells. Moreover, long-term surviving mice originally treated with DSR-29133 and RT were protected by a tumor-specific memory immune response which could prevent tumor growth upon rechallenge. These results demonstrate that DSR-29133 is a potent selective TLR7 agonist that when administered intravenously can induce anti-tumor immune responses that can be further enhanced through combination with low-dose fractionated RT.
Collapse
|
16
|
FRI0027 MRI-Proven Bone Marrow Oedema at Baseline is the Strongest Predictor Toward the Development of Rapid Radiographic Progression at 1 Year in Patients with Early-Stage Rheumatoid Arthritis: Results from Nagasaki University Early Arthritis Cohort. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5778] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
SAT0533 Early Diagnosis is Associated with the Less Flair in Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.3827] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
18
|
FRI0048 MRI Bone Erosion at Baseline Predicts the Subsequent Radiographic Progression in Early-Stage RA Patients Who Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.5527] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
19
|
SAT0088 Prognostic Factors Toward Rapid Radiographic Progression in Patients with Rheumatoid Arthritis in Clinical Practice: A Japanese Multicenter, Prospective Longitudinal Cohort Study for Achieving Treat to Target Strategy. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.2201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
20
|
SAT0173 Baseline Parameters Identified in Early, Methotrexate-Naïve Rheumatoid Arthritis Patients with Better Outcomes with Certolizumab Pegol+Methotrexate Compared to Placebo+Methotrexate: Post-Hoc Analyses of C-OPERA, A Randomized, Controlled, Phase 3 Study. Ann Rheum Dis 2015. [DOI: 10.1136/annrheumdis-2015-eular.1501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
21
|
Increased prevalence of MEFV exon 10 variants in Japanese patients with adult-onset Still's disease. Clin Exp Immunol 2015; 179:392-7. [PMID: 25286988 DOI: 10.1111/cei.12463] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/01/2014] [Indexed: 12/01/2022] Open
Abstract
Autoinflammatory diseases include a large spectrum of monogenic diseases, e.g. familial Mediterranean fever (FMF), as well as complex genetic trait diseases, e.g. adult-onset Still's disease (AOSD). In populations where FMF is common, an increased MEFV mutation rate is found in patients with rheumatic diseases. The aim of this study was to examine MEFV mutations in Japanese patients with AOSD. Genomic DNA was isolated from 49 AOSD patients and 105 healthy controls, and exons 1, 2, 3 and 10 of the MEFV gene genotyped by direct sequencing. MEFV mutation frequencies in AOSD patients were compared with controls. We found no significant difference in overall allele frequencies of MEFV variants between AOSD patients and controls. However, MEFV exon 10 variants (M694I and G632S) were significantly higher in AOSD patients than controls (6.1 versus 0%). In addition, there was no significant difference between MEFV variant carriers and non-carriers with clinical manifestations, but the monocyclic clinical course of the AOSD disease phenotype was observed less frequently in patients without MEFV variants. AOSD patients had significantly higher frequencies of MEFV exon 10 mutations, suggesting that low-frequency variants of MEFV gene may be one of the susceptibility factors of AOSD.
Collapse
|
22
|
Abstract
Subcutaneous fat necrosis associated with acute pancreatitis in a 54-year-old man was reported. The acute pancreatitis was proved histologically after gastrectomy for coincident early gastric carcinoma. The patient was successfully treated with prednisolone and his skin lesions subsided within a month.
Collapse
|
23
|
Effects of treadmill exercise on muscle fibers in mice with steroid myopathy. JOURNAL OF THE JAPANESE PHYSICAL THERAPY ASSOCIATION 2015; 4:25-7. [PMID: 25792922 DOI: 10.1298/jjpta.4.25] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/19/2000] [Accepted: 11/01/2000] [Indexed: 11/23/2022]
Abstract
We studied the effect of treadmill exercise on muscle fibers in mice with experimental steroid myopathy. Frozen sections of the extensor digitorum longus (EDL) and soleus (SOL) muscles were stained with hematoxylin-eosin, and the muscle fiber diameters measured. In the EDL, muscle fiber diameters in the steroid groups decreased significantly compared with those in the control groups; moreover, muscle fiber diameters in the exercise groups increased significantly compared with those in the non-exercise groups, whereas the diameters in the SOL did not differ. We speculate that treadmill exercise may prevent corticosteroid-induced muscle fiber atrophy.
Collapse
|
24
|
Effects of short duration stretching on disuse muscle atrophy in immobilized rat soleus muscles. JOURNAL OF THE JAPANESE PHYSICAL THERAPY ASSOCIATION 2015; 4:1-5. [PMID: 25792918 DOI: 10.1298/jjpta.4.1] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/1999] [Accepted: 04/01/2000] [Indexed: 11/23/2022]
Abstract
The purpose of this study was to determine whether short duration stretching is ameliorating for disuse muscle atrophy in immobilized rat soleus muscles. Eighteen male Wistar rats (age, 8 weeks; weight, 311.0 ± 35.6 g) were divided randomly into control (n=3) and experimental (n=15) groups. Bilateral ankles of each rat in the experimental group were fixed in full planter flexion with a plaster cast. After the experimental groups rats were immobilized for 4 weeks, animals were divided into three groups: immobilization alone (group I, n=3), stretch training for 30 min/day for 1 or 3 weeks after remobilization (group S, n=6), and spontaneous recovery (non stretch training) for 1 or 3 weeks after remobilization (group NS, n=6). At the end of the experimental periods, the soleus muscle was extracted from hindlimb, and the frozen sections were stained with myofibrillar adenosine triphosphatase. After 1 week of remobilization, the means of the muscle fiber diameters for type I fibers in group S had increased significantly compared with group NS, but those for type II fibers in group S did not significantly differ from that for group NS. After 3 weeks of remobilization, the means of the muscle fiber diameters for types I and II fibers in group S had increased significantly compared with group NS. No difference in the fiber type distribution were observed between the experimental group. Our findings suggest that short duration stretching induces recovery from disuse muscle atrophy after joint fixation.
Collapse
|
25
|
Ambulatory BP monitoring and clinic BP in predicting small-for-gestational-age infants during pregnancy. J Hum Hypertens 2015; 30:62-7. [DOI: 10.1038/jhh.2015.20] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 12/07/2014] [Accepted: 01/08/2015] [Indexed: 11/09/2022]
|
26
|
Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. Invest New Drugs 2014; 33:490-5. [PMID: 25502982 PMCID: PMC4387249 DOI: 10.1007/s10637-014-0197-z] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2014] [Accepted: 12/03/2014] [Indexed: 12/31/2022]
Abstract
Background Elpamotide is an HLA-A*24:02-restricted epitope peptide of vascular endothelial growth factor receptor 2 (VEGFR-2) and induces cytotoxic T lymphocytes (CTLs) against VEGFR-2/KDR. Given the high expression of VEGFR-2 in biliary tract cancer, combination chemoimmunotherapy with elpamotide and gemcitabine holds promise as a new therapy. Patients and Methods Patients with unresectable advanced or recurrent biliary tract cancer were included in this single-arm phase II trial, with the primary endpoint of overall survival. Survival analysis was performed in comparison with historical control data. The patients concurrently received gemcitabine once a week for 3 weeks (the fourth week was skipped) and elpamotide once a week for 4 weeks. Results Fifty-five patients were registered, of which 54 received the regimen and were included in the full analysis set as well as the safety analysis set. Median survival was 10.1 months, which was longer than the historical control, and the 1-year survival rate was 44.4 %. Of these patients, injection site reactions were observed in 64.8 %, in whom median survival was significantly longer (14.8 months) compared to those with no injection site reactions (5.7 months). The response rate was 18.5 %, and all who responded exhibited injection site reactions. Serious adverse reactions were observed in five patients (9 %), and there were no treatment-related deaths. Conclusion Gemcitabine and elpamotide combination therapy was tolerable and had a moderate antitumor effect. For future development of therapies, it will be necessary to optimize the target population for which therapeutic effects could be expected.
Collapse
|
27
|
Abstract 2217: Genomic alteration of bromodomain protein ATAD2 in cancer. Cancer Res 2014. [DOI: 10.1158/1538-7445.am2014-2217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
ATPase family, AAA domain containing 2 (ATAD2), is a member of the bromodomain-containing protein family. ATAD2 associates with co-factors such as hormone receptors, E2Fs and c-Myc to control a specific subset of genes. Overexpression and copy number alteration of ATAD2 are observed in many types of cancer, and these alterations are correlated with poor clinical outcome in breast, lung, and endometrial cancers. Here, we present an integrated genomic analysis of ATAD2 using the Oncomine™ database that shows cancer-associated features of ATAD2. In The Cancer Genome Atlas, amplifications of ATAD2 are observed in 63% of ovarian, 52% of breast, 39% of colorectal, and 18% of lung cancer patients. By contrast, no amplification of ATAD2 is observed in corresponding normal tissues. In most cases, amplifications are modest ranging up to a copy number of six. Moreover, a high correlation between ATAD2 mRNA expression levels and its copy number is observed in cultured cell lines. In order to investigate the role of the bromodomain in ATAD2, we conducted a cell-free physicochemical binding analysis and in vitro physiological studies using human colon cancer cells (HCT-116). To identify binding partners for the ATAD2 bromodomain, we constructed ATAD2 AlphaScreen systems and examined the binding activity of the ATAD2 bromodomain protein to various acetylated or non-acetylated histone peptides. The ATAD2 bromodomain interacted with histone H4 acetylated at lysine 5, 8 or 12, but not with other acetylated and non-acetylated histone peptides. Subcellular localization analysis by immunofluorescence, demonstrated that ATAD2 is mainly localizes to nucleus and that treatment with trichostatin A, an inhibitor of histone deacetylases increased nuclear ATAD2 protein levels, suggesting that the acetylation level of histone tails may affect ATAD2 expression or localization. In in silico expression analysis using the Cancer Cell Line Encyclopedia, showed most genes that correlated with ATAD2 expression have a role in proliferation or survival. To determine if the ATAD2 protein directly controls transcription of these genes, we performed ChIP-PCR assays and found that ATAD2 protein occupies the DNA promoter regions of downstream targets, eg. TOP2A, but does not occupy the promoters of non-target negative controls, such as β-actin. In conclusion, we show ATAD2 copy number alteration in a large number of cancer patients, suggesting that ATAD2 expression, or genomic alteration, may be useful prognostic markers of cancer. We also show that physicochemical binding of the ATAD2 bromodomain to specific acetylated histone peptides suggesting a physiological function of ATAD2 in nucleus as a transcriptional regulator of tumor-related genes. These results suggest that a blockade of ATAD2 bromodomain binding to specific acetylated histone tails may provide a novel approach to anti-tumor drug development.
Citation Format: Tomoyo Takeda, Yuta Matsumura, Hirotoshi Nagasaki, Ken Eguchi, Miki Takatsuka, Yoichi Shinkai, Hiroyuki Nakagawa, Hitoshi Kawashima, Hiroyuki Ueno, Chiang J. Li. Genomic alteration of bromodomain protein ATAD2 in cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2217. doi:10.1158/1538-7445.AM2014-2217
Collapse
|
28
|
|
29
|
Preliminary development and evaluation of the support system for care of mechanically ventilated patients. Br J Anaesth 2014; 113:491-500. [DOI: 10.1093/bja/aeu097] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Blood Pressure Variability/Dipper/Non-dipper in Hypertension and Diabetes. Curr Hypertens Rev 2014:CHYR-EPUB-61743. [PMID: 25115696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2014] [Accepted: 07/30/2014] [Indexed: 06/03/2023]
Abstract
It has been well recognized that hypertension in diabetes is a potent risk of micro- and macrovascular complications. BP levels are most important component of BP management. Next to BP levels, other component such as BP variability is also important. BP variability consists of several concepts [1] 1) Very Short term BP variability (beat-to-beat) 2) Short term BP variability (over the 24h) 3) Diurnal BP variation in diabetes 4) Long term BP variability (day-by-day) 5) Visit-to-Visit Variability (months ~ years) Among these, abnormal circadian rhythm of BP belongs to short-term BP variability. There have been a number of papers about BP variability in recent years. In this chapter, the significance of BP variability in patients with diabetes will be reviewed.
Collapse
|
31
|
MEFV gene polymorphisms and TNFRSF1A mutation in patients with inflammatory myopathy with abundant macrophages. Clin Exp Immunol 2014; 178:224-8. [PMID: 24965843 DOI: 10.1111/cei.12407] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/24/2014] [Indexed: 12/29/2022] Open
Abstract
Inflammatory myopathy with abundant macrophages (IMAM) has recently been proposed as a new clinical condition. Although IMAM shares certain similarities with other inflammatory myopathies, the mechanisms responsible for this condition remain unknown. Patients with familial Mediterranean fever (FMF) and tumour necrosis factor receptor-associated periodic syndrome (TRAPS) also often develop myalgia. We therefore investigated the polymorphisms or mutations of MEFV and TNFRSF1A genes in patients with IMAM to identify their potential role in this condition. We analysed the clinical features of nine patients with IMAM and sequenced exons of the MEFV and TNFRSF1A genes. The patients with IMAM had clinical symptoms such as myalgia, muscle weakness, erythema, fever and arthralgia. Although none of the patients were diagnosed with FMF or TRAPS, seven demonstrated MEFV polymorphisms (G304R, R202R, E148Q, E148Q-L110P and P369S-R408Q), and one demonstrated a TNFRSF1A mutation (C43R). These results suggest that MEFV gene polymorphisms and TNFRSF1A mutation are susceptibility and modifier genes in IMAM.
Collapse
|
32
|
A Japanese Region-wide Survey of the Knowledge, Difficulties and Self-reported Palliative Care Practices Among Nurses. Jpn J Clin Oncol 2014; 44:718-28. [DOI: 10.1093/jjco/hyu075] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
THU0190 Better Clinical Responses Seen Early with the Loading Dose of Certolizumab Pegol are Maintained until One Year. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1447] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
34
|
AB0219 Evaluation of the Japanese Patients with Rheumatoid Arthritis (RA) of RAPID Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4035] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
35
|
OP0225 Mefv and TNFRSF1A Gene Mutations in Patients with Inflammatory Myopathy with Abundant Macrophages. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
36
|
AB1018 Articular Synovitis or Tenosynovitis - Which is More Involved toward Functional Disabilities in Patients with Rheumatoid Arthritis? Investigation of Wrist and Finger Joints by Ultrasound in Early-Stage Rheumatoid Arthritis. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
37
|
OP0117 Surveillance of the Outcome of Remitting Seronegative Symmetrical Synovitis with Pitting Edema (RS3PE) Syndrome. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.4160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
38
|
SAT0215 Ultrasound Disease Activity at 3 Months Predicts the Clinical Response at 6 Months of Patients with Rheumatoid Arthritis Treated by Biologic Disease Modifying Anti-Rheumatic Drugs. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.2574] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
39
|
FRI0278 The First Early Rheumatoid Arthritis, Certolizumab Pegol, Multicenter, Double-Blind, Randomized, Parallel-Group Study: C-Opera, in Patients Fulfilling the 2010 Acr/Eular Classification Criteria, Demonstrates Inhibition of Joint Damage Progression. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2014-eular.1448] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
40
|
|
41
|
Synovial inflammation assessed by ultrasonography correlates with MRI-proven osteitis in patients with rheumatoid arthritis. Rheumatology (Oxford) 2014; 53:1452-6. [DOI: 10.1093/rheumatology/keu034] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
42
|
THU0121 Characteristic of the Japanese Patients with Rheumatoid Arthritis (RA) of Rapid Radiographic Progression (RRP) Treated with Synthetic Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Daily Practice: A Large-Scale Prospective Longitudinal Cohort Study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2013-eular.649] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
43
|
AB0574 Evaluation of the efficacy of tocilizumab toward the patients with active rheumatoid arthritis of nagasaki prefecture, japan. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.574] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
44
|
AB0468 Improved physical function, pain, and health related quality of life with certolizumab pegol in japanese rheumatoid arthritis patients with an inadequate response to methotrexate: Results from the jrapid study. Ann Rheum Dis 2014. [DOI: 10.1136/annrheumdis-2012-eular.468] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
45
|
Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol 2014; 174:356-63. [PMID: 23968543 DOI: 10.1111/cei.12190] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2013] [Indexed: 12/15/2022] Open
Abstract
Janus kinase (JAK) inhibitors have been developed as anti-inflammatory agents and have demonstrated clinical efficacy in rheumatoid arthritis (RA). We investigated if JAK-3-selective inhibition alone could disrupt cytokine signalling in rheumatoid synovial fibroblasts. In-vitro studies were performed using synovial fibroblasts isolated from patients with RA. Levels of activated JAK and signal transducer and activator of transcription (STAT) proteins were detected by immunoblot analysis. Target-gene expression levels were measured by reverse transcription-polymerase chain reaction (RT-PCR) or real-time PCR. The JAK inhibitors CP-690,550 and INCB028050 both suppressed activation of JAK-1/-2/-3 and downstream STAT-1/-3/-5, as well as the expression levels of target proinflammatory genes (MCP-I, SAA1/2) in oncostatin-M (OSM)-stimulated rheumatoid synovial fibroblasts. In contrast, the JAK-3-selective inhibitor, PF-956980, suppressed STAT-1/-5 activation but did not affect STAT-3 activation in OSM-stimulated rheumatoid synovial fibroblasts. In addition, PF-956980 significantly suppressed MCP-1 gene expression, but did not block SAA1/2 gene expression in OSM-stimulated rheumatoid synovial fibroblasts. These data suggest that JAK-3-selective inhibition alone is insufficient to control STAT-3-dependent signalling in rheumatoid synovial fibroblasts, and inhibition of JAKs, including JAK-1/-2, is needed to control the proinflammatory cascade in RA.
Collapse
|
46
|
Abstract
Abstract We report two cases of rheumatoid arthritis (RA) with atypical mycobacteriosis. Opportunistic infections are critical complications for rheumatic diseases. The use of steroids or immunosuppressants may increase the risk of opportunistic infections. However, these reports are rare in that they demonstrate atypical mycobacterial infections as complications of RA, even though no immunosuppressive agents were used. We discuss the characteristics of atypical mycobacterial infections of the lung in RA.
Collapse
|
47
|
|
48
|
Role of HTLV-I infection in the pathogenesis of Sjögren's syndrome and rheumatoid arthritis. Mod Rheumatol 2014; 11:87-90. [DOI: 10.3109/s101650170018] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
49
|
|
50
|
A Randomized, Double-Blind, Placebo-Controlled PIII Study of Fentanyl Buccal Tablet (FBT) for Breakthrough Cancer Pain. Ann Oncol 2013. [DOI: 10.1093/annonc/mdt459.20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|